Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well dasatinib works in treating patients with malignant
salivary gland tumors that have come back after treatment or have spread to other parts of
the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth.